Notably, p28 peptide, an anti-glioma drug, specifically dampens the COP1-p53 binding and stabilizes p53 from degradation31, and our structural analyses showed that there are overlaps between azurin binding sites and reported ubiquitin E3 ligase COP1 binding sites on p5314,32. Here, COP1 is linked to central nervous system cancer.